FDA Approves HRT Label Changes
The agency cited updated evidence in revising hormone therapy safety language.
-
By
-
Kathryn Wighton
-
February 12, 2026
-
Clinical Scorecard: FDA Approves HRT Label Changes
At a Glance
| Category | Detail |
|---|
| Condition | Menopausal symptoms including hot flashes, vaginal dryness, and bone loss |
| Key Mechanisms | Hormone replacement therapy (HRT) alleviates vasomotor symptoms and prevents bone loss |
| Target Population | Women experiencing menopause, particularly those aged 45 to 64 years |
| Care Setting | Outpatient settings, including primary care and gynecology |
Key Highlights
- Removal of cardiovascular disease, breast cancer, and probable dementia risk statements from boxed warnings
- Approval of six menopausal hormone therapy products across four categories
- Initiation of labeling updates by the FDA in November 2025
- Evidence supports benefits of HRT when initiated within 10 years of menopause onset
- Low utilization of hormone therapy among eligible women despite significant potential benefits
Guideline-Based Recommendations
Diagnosis
- Assess menopausal symptoms and quality of life impact
Management
- Consider HRT for moderate to severe vasomotor symptoms and prevention of osteoporosis
Monitoring & Follow-up
- Regular follow-up to assess symptom relief and any potential side effects
Risks
- Monitor for any emerging safety concerns despite removal of previous boxed warnings
Patient & Prescribing Data
Approximately 41 million US women aged 45 to 64 years
Only about 2 million women aged 46 to 65 years received a prescription for hormone therapy in 2020
Clinical Best Practices
- Educate patients on the benefits and risks of HRT
- Encourage timely initiation of therapy for optimal outcomes
- Utilize shared decision-making to tailor treatment plans
References
